Cargando…

An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands

INTRODUCTION: Vaccination against human papillomavirus (HPV) is considered the most effective strategy to protect women from cervical cancer. Three HPV vaccines are currently licensed in Europe and, although they are generally supported by favorable health economic outcomes, current models fall shor...

Descripción completa

Detalles Bibliográficos
Autores principales: Luttjeboer, Jos, Simons, Joost, Westra, Tjalke, Wilschut, Jan, Boersma, Cornelis, Postma, Maarten, van der Schans, Jurjen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505117/
https://www.ncbi.nlm.nih.gov/pubmed/37563438
http://dx.doi.org/10.1007/s40121-023-00851-9
_version_ 1785106851040329728
author Luttjeboer, Jos
Simons, Joost
Westra, Tjalke
Wilschut, Jan
Boersma, Cornelis
Postma, Maarten
van der Schans, Jurjen
author_facet Luttjeboer, Jos
Simons, Joost
Westra, Tjalke
Wilschut, Jan
Boersma, Cornelis
Postma, Maarten
van der Schans, Jurjen
author_sort Luttjeboer, Jos
collection PubMed
description INTRODUCTION: Vaccination against human papillomavirus (HPV) is considered the most effective strategy to protect women from cervical cancer. Three HPV vaccines are currently licensed in Europe and, although they are generally supported by favorable health economic outcomes, current models fall short in predicting vaccination benefits. Here, we aim to re-evaluate the health benefits of HPV vaccination, using updated long-term effectiveness data and emphasizing quality of life losses related to pre-cancer disease and treatment. METHODS: We used a static Markov model that compared “only screening” (includes unvaccinated girls) and “vaccination” (assumes 100% vaccination coverage with the bivalent HPV vaccine). A lifetime cohort of 100,000 uninfected 12-year-old girls was included, in which the number of cases with cervical intraepithelial neoplasia grade 2 or higher/3 (CIN2+, CIN3), cervical cancer, and cervical cancer deaths per scenario were determined. Furthermore, the reduction in major excisional procedures, the preterm deliveries averted, and the related gain in quality-adjusted life years (QALYs) due to vaccination were estimated. RESULTS: The bivalent vaccine showed larger reductions in CIN2+, CIN3, cervical cancer cases, cervical cancer deaths, and major excisional treatments, after including long-term efficacy and effectiveness data, compared to previous data. Moreover, we observed an increased amount of QALYs gained due to prevention of major excisional treatment and the negative side effects related to it. CONCLUSIONS: Updated health economic models for HPV vaccination, using updated and long-term effectiveness data and including prevention of treatment-related side effects, demonstrate a substantial additional positive effect on vaccination outcomes. Indeed, extrapolation of the bivalent HPV vaccine’s updated long-term effectiveness data against HPV-related cervical diseases shows that the positive effects of vaccination may be more substantial than previously estimated. There is a graphical abstract available for this article. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-023-00851-9.
format Online
Article
Text
id pubmed-10505117
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-105051172023-09-18 An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands Luttjeboer, Jos Simons, Joost Westra, Tjalke Wilschut, Jan Boersma, Cornelis Postma, Maarten van der Schans, Jurjen Infect Dis Ther Original Research INTRODUCTION: Vaccination against human papillomavirus (HPV) is considered the most effective strategy to protect women from cervical cancer. Three HPV vaccines are currently licensed in Europe and, although they are generally supported by favorable health economic outcomes, current models fall short in predicting vaccination benefits. Here, we aim to re-evaluate the health benefits of HPV vaccination, using updated long-term effectiveness data and emphasizing quality of life losses related to pre-cancer disease and treatment. METHODS: We used a static Markov model that compared “only screening” (includes unvaccinated girls) and “vaccination” (assumes 100% vaccination coverage with the bivalent HPV vaccine). A lifetime cohort of 100,000 uninfected 12-year-old girls was included, in which the number of cases with cervical intraepithelial neoplasia grade 2 or higher/3 (CIN2+, CIN3), cervical cancer, and cervical cancer deaths per scenario were determined. Furthermore, the reduction in major excisional procedures, the preterm deliveries averted, and the related gain in quality-adjusted life years (QALYs) due to vaccination were estimated. RESULTS: The bivalent vaccine showed larger reductions in CIN2+, CIN3, cervical cancer cases, cervical cancer deaths, and major excisional treatments, after including long-term efficacy and effectiveness data, compared to previous data. Moreover, we observed an increased amount of QALYs gained due to prevention of major excisional treatment and the negative side effects related to it. CONCLUSIONS: Updated health economic models for HPV vaccination, using updated and long-term effectiveness data and including prevention of treatment-related side effects, demonstrate a substantial additional positive effect on vaccination outcomes. Indeed, extrapolation of the bivalent HPV vaccine’s updated long-term effectiveness data against HPV-related cervical diseases shows that the positive effects of vaccination may be more substantial than previously estimated. There is a graphical abstract available for this article. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-023-00851-9. Springer Healthcare 2023-08-10 2023-08 /pmc/articles/PMC10505117/ /pubmed/37563438 http://dx.doi.org/10.1007/s40121-023-00851-9 Text en © GSK 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Luttjeboer, Jos
Simons, Joost
Westra, Tjalke
Wilschut, Jan
Boersma, Cornelis
Postma, Maarten
van der Schans, Jurjen
An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands
title An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands
title_full An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands
title_fullStr An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands
title_full_unstemmed An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands
title_short An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands
title_sort updated analysis of the impact of hpv vaccination based on long-term effectiveness in the netherlands
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505117/
https://www.ncbi.nlm.nih.gov/pubmed/37563438
http://dx.doi.org/10.1007/s40121-023-00851-9
work_keys_str_mv AT luttjeboerjos anupdatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT simonsjoost anupdatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT westratjalke anupdatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT wilschutjan anupdatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT boersmacornelis anupdatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT postmamaarten anupdatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT vanderschansjurjen anupdatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT luttjeboerjos updatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT simonsjoost updatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT westratjalke updatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT wilschutjan updatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT boersmacornelis updatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT postmamaarten updatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands
AT vanderschansjurjen updatedanalysisoftheimpactofhpvvaccinationbasedonlongtermeffectivenessinthenetherlands